COHERUS BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.04 USD | +5.70% |
|
-1.45% | -38.74% |
| Sales 2024 * | 262M 20.89B | Sales 2025 * | 357M 28.5B | Capitalization | 232M 18.47B |
|---|---|---|---|---|---|
| Net income 2024 * | -69M -5.5B | Net income 2025 * | -20M -1.6B | EV / Sales 2024 * | 1.91 x |
| Net Debt 2024 * | 268M 21.4B | Net Debt 2025 * | 286M 22.83B | EV / Sales 2025 * | 1.45 x |
| P/E ratio 2024 * |
-3.71
x | P/E ratio 2025 * |
-18.9
x | Employees | 306 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.92% |
More Fundamentals
* Assessed data
More news
Latest transcript on Coherus BioSciences, Inc.
More recommendations
More press releases
More news
| 1 day | +5.70% | ||
| 1 week | -1.45% | ||
| Current month | -14.64% | ||
| 1 month | -14.64% | ||
| 3 months | -12.82% | ||
| 6 months | -22.73% | ||
| Current year | -38.74% |
1 week
1.91
2.25
1 month
1.912.61
Current year
1.913.70
1 year
1.438.22
3 years
1.4319.32
5 years
1.4323.91
10 years
1.4338.10
| Managers | Title | Age | Since |
|---|---|---|---|
Denny Lanfear
CEO | Chief Executive Officer | 68 | 31/08/10 |
Bryan Mcmichael
DFI | Director of Finance/CFO | 46 | 28/02/21 |
| Chief Tech/Sci/R&D Officer | - | 30/11/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mark Stolper
BRD | Director/Board Member | 52 | 04/01/21 |
Mats Wahlström
BRD | Director/Board Member | 70 | 31/12/11 |
Ali Satvat
BRD | Director/Board Member | 46 | 30/04/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 0 M€ | 0.00% | - | |
| 0.06% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 2.04 | +5.70% | 907,176 |
| 25/04/24 | 1.93 | -4.46% | 2,220,138 |
| 24/04/24 | 2.02 | -7.34% | 879,713 |
| 23/04/24 | 2.18 | 0.00% | 811,796 |
| 22/04/24 | 2.18 | +5.31% | 1,499,626 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.04
USD
Average target price
7.8
USD
Spread / Average Target
+282.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.74% | 232M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CHRS Stock
